D-retro-inverso peptide designed to disrupt FOXO4–p53 interaction
PRODUCT PROFILE
FOXO4-DRI
£92.00
FOXO4-DRI is d-retro-inverso peptide designed to disrupt foxo4–p53 interaction. Researchers examine it in relation to selective removal of senescent cells in ageing models.
Why it is distinct
A targeted experimental senolytic mechanism, not a mitochondrial support or endocrine peptide.
- Evidence stagePreclinical
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
FOXO4-DRI is d-retro-inverso peptide designed to disrupt foxo4–p53 interaction. Researchers examine it in relation to selective removal of senescent cells in ageing models.
Research focus+
Researchers study whether disrupting one cell-survival interaction can help remove these senescent cells. Evidence is preclinical and it is not a proven anti-ageing treatment.
How the mechanism differs+
In preclinical models, releases p53 from FOXO4 sequestration to promote apoptosis preferentially in senescent cells.
Evidence and limitations+
Compelling mouse proof-of-concept but no established controlled human clinical evidence.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study whether disrupting one cell-survival interaction can help remove these senescent cells. Evidence is preclinical and it is not a proven anti-ageing treatment.
In preclinical models, releases p53 from FOXO4 sequestration to promote apoptosis preferentially in senescent cells.
A targeted experimental senolytic mechanism, not a mitochondrial support or endocrine peptide.
Compelling mouse proof-of-concept but no established controlled human clinical evidence.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Endoluten
£46.0020 mgBatch file pendingPineal/circadian branding with uncertain composition, distinct from sequence-defined Epithalon.
UnavailableAsk about availability -
Preclinical
Epithalon
£58.0010 mgBatch file pendingA proposed pineal-derived bioregulator with telomere-focused claims, not a mitochondrial-targeting peptide.
UnavailableAsk about availability -
Experimental
Vesugen
£46.0020 mgBatch file pendingVascular-tissue focus distinguishes it from mitochondrial or general healthy-ageing peptides.
UnavailableAsk about availability -
Preclinical
Humanin
£68.0010 mgBatch file pendingPrimarily cytoprotective/anti-apoptotic, whereas MOTS-c centres on metabolic stress signalling.
UnavailableAsk about availability